Bijan Boldajipour

3.9k citations

20 papers · 2.9k indexed · 3 hit papers · h-index 15

Co-authors: Erez Raz Matthew F. Krummel Michal Reichman‐Fried Eléna Kardash Amanda E. Nelson Harsha Mahabaleshwar Sebastián Amigorena Anne I. Sperling
Topics: CAR-T cell therapy research (10 papers)Immunotherapy and Immune Responses (8 papers)Viral Infectious Diseases and Gene Expression in Insects (4 papers)
Cited by: Immunology Oncology Cancer Research
Journals: Cell Nature Communications Blood
Partner nations: United States Germany France

In The Last Decade

Bijan Boldajipour

19 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

2014 889 citations Miranda L. Broz, Mikhail Binnewies et al. Cancer Cell profile →
RNA-Binding Protein Dnd1 Inhibits MicroRNA Access to Target mRNA

2007 591 citations Martijn Kedde, Bijan Boldajipour et al. Cell profile →
Control of Chemokine-Guided Cell Migration by Ligand Sequestration

2008 506 citations Bijan Boldajipour, Harsha Mahabaleshwar et al. Cell profile →

Peers

Countries citing papers authored by Bijan Boldajipour

Since Specialization

Citations

This map shows the geographic impact of Bijan Boldajipour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bijan Boldajipour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bijan Boldajipour more than expected).

Fields of papers citing papers by Bijan Boldajipour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bijan Boldajipour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bijan Boldajipour. The network helps show where Bijan Boldajipour may publish in the future.

Co-authorship network of co-authors of Bijan Boldajipour

This figure shows the co-authorship network connecting the top 25 collaborators of Bijan Boldajipour. A scholar is included among the top collaborators of Bijan Boldajipour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bijan Boldajipour. Bijan Boldajipour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation 2024 ·Scientific Reports ·Aileen W. Li,Jessica Briones,Jia Lü,Q. David Walker,(unknown),Hajime Hiraragi,Bijan Boldajipour,Purnima Sundar,Shobha Potluri,Gary Lee,Omar A. Ali,Alexander S. Cheung	3
2	Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling 2022 ·Cancer Immunology Research ·Regina Lin,Andrew R. Nager,Spencer Park,Janette Sutton,(unknown),Zea Melton,(unknown),Bijan Boldajipour,Thomas Van Blarcom,Siler H. Panowski,Barbra J. Sasu,Javier Chaparro‐Riggers	6
3	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors 2022 ·Cancer Research Communications ·Ana M. Metelo,Agnieszka Jóźwik,Le Anh Luong,(unknown),Charlotte Graham,(unknown),(unknown),Alan Dunlop,(unknown),Kirsty Cuthill,Carmel Rice,Matthew Streetly,Trevor Bentley,Bijan Boldajipour,Cesar Sommer,Barbra J. Sasu,Reuben Benjamin	17
4	Direct control of CAR T cells through small molecule-regulated antibodies 2021 ·Nature Communications ·Spencer Park,Edward Pascua,Kevin C. Lindquist,Christopher R. Kimberlin,Xiaodi Deng,Yvonne S.L. Mak,Zea Melton,Theodore Johnson,Regina Lin,Bijan Boldajipour,Robert T. Abraham,Jaume Pons,Barbra J. Sasu,Thomas Van Blarcom,Javier Chaparro‐Riggers	38
5	Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups 2019 ·Blood ·Ana M. Metelo,(unknown),Agnieszka Jóźwik,Charlotte Graham,(unknown),(unknown),Alan Dunlop,Kirsty Cuthill,Carmel Rice,Matthew Streetly,Trevor Bentley,Bijan Boldajipour,Cesar Sommer,Barbra J. Sasu,Reuben Benjamin	2
6	A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies 2018 ·Scientific Reports ·Julien Valton,Valérie Guyot,Bijan Boldajipour,Cesar Sommer,Thomas Pertel,Alexandre Juillerat,Aymeric Duclert,Barbra J. Sasu,Philippe Duchâteau,Laurent Poirot	28
7	ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma 2018 ·Blood ·Cesar Sommer,Bijan Boldajipour,Julien Valton,Román Galetto,Trevor Bentley,Janette Sutton,Yajin Ni,(unknown),Thomas Van Blarcom,Julianne Smith,Javier Chaparro‐Riggers,Barbra J. Sasu	14
8	Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine 2016 ·JCI Insight ·Bijan Boldajipour,Amanda E. Nelson,Matthew F. Krummel	24
9	Preclinical Evaluation of Allogeneic Anti-Bcma Chimeric Antigen Receptor T Cells with Safety Switch Domains and Lymphodepletion Resistance for the Treatment of Multiple Myeloma 2016 ·Blood ·Bijan Boldajipour,Román Galetto,Cesar Sommer,Thomas Pertel,Julien Valton,Yoon Park,(unknown),Amy Chen,(unknown),(unknown),(unknown),Thomas Van Blarcom,Javier Chaparro‐Riggers,Arvind Rajpal,(unknown),Tracy C. Kuo,Barbra J. Sasu	4
10	Adaptive Immune Regulation of Mammary Postnatal Organogenesis 2015 ·Developmental Cell ·Vicki Plaks,Bijan Boldajipour,Jelena R. Linnemann,Nguyen Hoai Nguyen,Kelly Kersten,Yochai Wolf,Amy-Jo Casbon,Niwen Kong,Renske J.E. van den Bijgaart,Dean Sheppard,Andrew C. Melton,Matthew F. Krummel,Zena Werb	81
11	Abstract B65: Dissecting the tumor myeloid compartment reveals rare activating antigen presenting cells, critical for T cell immunity 2015 ·Cancer Immunology Research ·Miranda L. Broz,Mikhail Binnewies,Bijan Boldajipour,Amanda E. Nelson,(unknown),David J. Erle,Andrea J. Barczak,Michael D. Rosenblum,Adil Daud,Diane L. Barber,Sebastián Amigorena,Laura van ‘t Veer,Anne I. Sperling,Denise M. Wolf,Matthew F. Krummel	0
12	Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity 2014 ·Cancer Cell ·Miranda L. Broz,Mikhail Binnewies,Bijan Boldajipour,Amanda E. Nelson,Joshua L. Pollack,David J. Erle,Andrea J. Barczak,Michael Rosenblum,Adil Daud,Diane L. Barber,Sebastián Amigorena,Laura J. van’t Veer,Anne I. Sperling,Denise M. Wolf,Matthew F. Krummel	114
13	Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunitybreakdown → 2014 ·Cancer Cell ·Miranda L. Broz,Mikhail Binnewies,Bijan Boldajipour,Amanda E. Nelson,Joshua L. Pollack,David J. Erle,Andrea J. Barczak,Michael D. Rosenblum,Adil Daud,Diane L. Barber,Sebastián Amigorena,Laura J. van’t Veer,Anne I. Sperling,Denise M. Wolf,Matthew F. Krummel	889
14	Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T Cells 2012 ·Cancer Cell ·John Engelhardt,Bijan Boldajipour,Peter Beemiller,(unknown),Caitlin M. Sorensen,Zena Werb,Mikala Egeblad,Matthew F. Krummel	266
15	Cxcl12 evolution – subfunctionalization of a ligand through altered interaction with the chemokine receptor 2011 ·Development ·Bijan Boldajipour,Maria Doitsidou,Katsiaryna Tarbashevich,Cédric Laguri,(unknown),Jonas Ries,Karin Dumstrei,Sylvia Thelen,(unknown),(unknown),Marcus Thelen,Petra Schwille,Michael Brand,Hugues Lortat‐Jacob,Erez Raz	25
16	A role for Rho GTPases and cell–cell adhesion in single-cell motility in vivo 2009 ·Nature Cell Biology ·Eléna Kardash,Michal Reichman‐Fried,Jean‐Léon Maître,Bijan Boldajipour,Ekaterina Papusheva,(unknown),Carl‐Philipp Heisenberg,Erez Raz	213
17	Control of Chemokine-Guided Cell Migration by Ligand Sequestrationbreakdown → 2008 ·Cell ·Bijan Boldajipour,Harsha Mahabaleshwar,Eléna Kardash,Michal Reichman‐Fried,Heiko Blaser,(unknown),Duncan Wilson,Qiling Xu,Erez Raz	506
18	Killing the messenger 2008 ·Cell Adhesion & Migration ·Harsha Mahabaleshwar,Bijan Boldajipour,Erez Raz	51
19	RNA-Binding Protein Dnd1 Inhibits MicroRNA Access to Target mRNAbreakdown → 2007 ·Cell ·Martijn Kedde,(unknown),Bijan Boldajipour,Joachim A.F. Oude Vrielink,Krasimir Slanchev,Carlos le Sage,Remco Nagel,P. Mathijs Voorhoeve,(unknown),Ulf Andersson Ørom,Anders H. Lund,Anastassis Perrakis,Erez Raz,Reuven Agami	591
20	What Is Left Behind—Quality Control in Germ Cell Migration 2007 ·Science s STKE ·Bijan Boldajipour,Erez Raz	22

About Bijan Boldajipour

Bijan Boldajipour is a scholar working on Immunology, Oncology and Immunology and Allergy, having authored 20 papers that have together received 2.9k indexed citations. Recurring topics across this work include CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). The work is most often cited by research in Immunology (1.5k citations), Oncology (1.4k citations) and Cancer Research (391 citations). Bijan Boldajipour has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Erez Raz, Matthew F. Krummel, Michal Reichman‐Fried, Eléna Kardash, Amanda E. Nelson, Harsha Mahabaleshwar, Sebastián Amigorena, Anne I. Sperling, Denise M. Wolf and Diane L. Barber. Their work appears in journals such as Cell, Nature Communications and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact